Suh-Hang Juo received MD degree and clinical neurology training in Taiwan. Then he devoted himself to research and received a master degree in cardiovascular epidemiology at Harvard University, PhD in genetic epidemiology at Johns Hopkins University, and post-doc training at the Rockefeller University and NIH.
He has been a faculty member at the Columbia University Genome Centerin New York City, and Kaohsiung Medical University in Kaohsiung Taiwan. Now he works at the China Medical University in Taichung Taiwan.
His current research focuses on (1) the progression of atherosclerosis based on a longitudinal cohort, (2) neurovascucular cross talk, (3) microRNAs in atherosclerosis and (4) neural stem cells.
Where do you see the industry in the next 20 years?: with increasing aging population, vascular dementia or cognitive impairment can be a big market for new drug/therapy development.
Please provide a quote which explains why you are so excited about participating in APSC 2017?: interaction with experts from regional experts